FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3025786513> ?p ?o ?g. }

• W3025786513 endingPage "270" @default.
• W3025786513 startingPage "262" @default.
• W3025786513 abstract "Background: Aptamers represent an emerging class of oligonucleotides that have the ability to bind ligands with high affinity. Sgc8-c aptamer recognizes PTK7, a member of the catalytically defective receptor protein tyrosine kinase family that is upregulated in various cancers, including hemato-oncological malignancies. Herein, an Sgc8-c-NOTA-radiolabeled probe was prepared for theranostic purpose. Materials and Methods: In this work, an Sgc8-c-radiolabeled probe against PTK7 was prepared, and biological evaluations—pharmacokinetic studies, biodistribution analysis, and in vivo molecular imaging—were performed. To obtain the radiolabeled probe, a modified 5′-amino-derivative of the Sgc8-c aptamer was bound to the metal chelator NOTA, and subsequently labeled with 67Ga with high yield and radiochemical purity. The precursor, Sgc8-c-NOTA, the radio probe Sgc8-c-NOTA-67Ga, and its nonradioactive complex, Sgc8-c-NOTA-69/71Ga, were purified by reverse-phase high-performance liquid chromatography and characterized by electrospray ionization mass spectrometry. The binding ability of Sgc8-c-NOTA-67Ga was studied in vitro against purified PTK7 receptor. In addition, the binding was also evidenced against the hemato-oncological A20 cell line, derived from B lymphocytes, and the corresponding A20-green fluorescent protein (GFP)-transfected cells. The proof of concept was performed on A20-GFP tumor-bearing mice, in which the biodistribution of the radiolabeled probe was evaluated through imaging, using X-ray, fluorescence, and γ modalities. The specific uptake of the probe was confirmed by blocking with the Sgc8-c aptamer in an in vivo competition assay. Results: The biodistribution results showed considerable uptake in tumor since 2 h, with highest at 48 h postinjection. However, the blood and muscle ID/g (injected dose per gram of tissue) activities were decreasing with time and tumor/no-target ratios increasing to 20 at 24 h postinjection. These results are consistent with the in vivo images. Conclusions: This study supports the utility of Sgc8-c-NOTA radiolabeled as a theranostic agent." @default.
• W3025786513 created "2020-05-21" @default.
• W3025786513 creator A5008769115 @default.
• W3025786513 creator A5016610740 @default.
• W3025786513 creator A5024816595 @default.
• W3025786513 creator A5049255660 @default.
• W3025786513 creator A5062887834 @default.
• W3025786513 creator A5070616267 @default.
• W3025786513 creator A5080927889 @default.
• W3025786513 creator A5090661133 @default.
• W3025786513 date "2020-05-01" @default.
• W3025786513 modified "2023-10-17" @default.
• W3025786513 title "Sgc8-c Aptamer as a Potential Theranostic Agent for Hemato-Oncological Malignancies" @default.
• W3025786513 cites W1959247563 @default.
• W3025786513 cites W1977700385 @default.
• W3025786513 cites W1979483334 @default.
• W3025786513 cites W2002387564 @default.
• W3025786513 cites W2002602850 @default.
• W3025786513 cites W2028167617 @default.
• W3025786513 cites W2038551857 @default.
• W3025786513 cites W2059281433 @default.
• W3025786513 cites W2064036940 @default.
• W3025786513 cites W2106582055 @default.
• W3025786513 cites W2137654190 @default.
• W3025786513 cites W2170219140 @default.
• W3025786513 cites W2206811867 @default.
• W3025786513 cites W2208373567 @default.
• W3025786513 cites W2283347044 @default.
• W3025786513 cites W2549659896 @default.
• W3025786513 cites W2554356944 @default.
• W3025786513 cites W2567223794 @default.
• W3025786513 cites W2688483731 @default.
• W3025786513 cites W2726109671 @default.
• W3025786513 cites W2740994733 @default.
• W3025786513 cites W2767027763 @default.
• W3025786513 cites W2800215895 @default.
• W3025786513 cites W2804086091 @default.
• W3025786513 cites W2807424937 @default.
• W3025786513 cites W2889968661 @default.
• W3025786513 cites W2892200679 @default.
• W3025786513 cites W2892204377 @default.
• W3025786513 cites W2892586379 @default.
• W3025786513 cites W2946221907 @default.
• W3025786513 cites W2980467008 @default.
• W3025786513 doi "https://doi.org/10.1089/cbr.2019.3402" @default.
• W3025786513 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32407201" @default.
• W3025786513 hasPublicationYear "2020" @default.
• W3025786513 type Work @default.
• W3025786513 sameAs 3025786513 @default.
• W3025786513 citedByCount "15" @default.
• W3025786513 countsByYear W30257865132021 @default.
• W3025786513 countsByYear W30257865132022 @default.
• W3025786513 countsByYear W30257865132023 @default.
• W3025786513 crossrefType "journal-article" @default.
• W3025786513 hasAuthorship W3025786513A5008769115 @default.
• W3025786513 hasAuthorship W3025786513A5016610740 @default.
• W3025786513 hasAuthorship W3025786513A5024816595 @default.
• W3025786513 hasAuthorship W3025786513A5049255660 @default.
• W3025786513 hasAuthorship W3025786513A5062887834 @default.
• W3025786513 hasAuthorship W3025786513A5070616267 @default.
• W3025786513 hasAuthorship W3025786513A5080927889 @default.
• W3025786513 hasAuthorship W3025786513A5090661133 @default.
• W3025786513 hasBestOaLocation W30257865131 @default.
• W3025786513 hasConcept C128972844 @default.
• W3025786513 hasConcept C129312508 @default.
• W3025786513 hasConcept C145169222 @default.
• W3025786513 hasConcept C150903083 @default.
• W3025786513 hasConcept C153911025 @default.
• W3025786513 hasConcept C185592680 @default.
• W3025786513 hasConcept C202751555 @default.
• W3025786513 hasConcept C204628709 @default.
• W3025786513 hasConcept C207001950 @default.
• W3025786513 hasConcept C2777807558 @default.
• W3025786513 hasConcept C2778172261 @default.
• W3025786513 hasConcept C552990157 @default.
• W3025786513 hasConcept C55493867 @default.
• W3025786513 hasConcept C86803240 @default.
• W3025786513 hasConceptScore W3025786513C128972844 @default.
• W3025786513 hasConceptScore W3025786513C129312508 @default.
• W3025786513 hasConceptScore W3025786513C145169222 @default.
• W3025786513 hasConceptScore W3025786513C150903083 @default.
• W3025786513 hasConceptScore W3025786513C153911025 @default.
• W3025786513 hasConceptScore W3025786513C185592680 @default.
• W3025786513 hasConceptScore W3025786513C202751555 @default.
• W3025786513 hasConceptScore W3025786513C204628709 @default.
• W3025786513 hasConceptScore W3025786513C207001950 @default.
• W3025786513 hasConceptScore W3025786513C2777807558 @default.
• W3025786513 hasConceptScore W3025786513C2778172261 @default.
• W3025786513 hasConceptScore W3025786513C552990157 @default.
• W3025786513 hasConceptScore W3025786513C55493867 @default.
• W3025786513 hasConceptScore W3025786513C86803240 @default.
• W3025786513 hasIssue "4" @default.
• W3025786513 hasLocation W30257865131 @default.
• W3025786513 hasOpenAccess W3025786513 @default.
• W3025786513 hasPrimaryLocation W30257865131 @default.
• W3025786513 hasRelatedWork W195104910 @default.
• W3025786513 hasRelatedWork W1970008822 @default.
• W3025786513 hasRelatedWork W1981183975 @default.

• next